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Abstract
Rift Valley fever Virus (RVFV), a negative-stranded RNA virus, is the etiological agent of the
vector-borne zoonotic disease, Rift Valley fever (RVF). In both humans and livestock, pro-
tective immunity can be achieved through vaccination. Earlier and more recent vaccine tri-
als in cattle and sheep demonstrated a strong neutralizing antibody and total IgG response
induced by the RVF vaccine, authentic recombinant MP-12 (arMP-12). From previous work,
protective immunity in sheep and cattle vaccinates normally occurs from 7 to 21 days after
inoculation with arMP-12. While the serology and protective response induced by arMP-12
has been studied, little attention has been paid to the underlying molecular and genetic
events occurring prior to the serologic immune response. To address this, we isolated RNA
from whole blood of vaccinated calves over a time course of 21 days before and after vacci-
nation with arMP-12. The time course RNAs were sequenced by RNASeq and bioinformati-
cally analyzed. Our results revealed time-dependent activation or repression of numerous
gene ontologies and pathways related to the vaccine induced immune response and its reg-
ulation. Additional bioinformatic analyses identified a correlative relationship between spe-
cific host immune response genes and protective immunity prior to the detection of
protective serum neutralizing antibody responses. These results contribute an important
proof of concept for identifying molecular and genetic components underlying the immune
response to RVF vaccination and protection prior to serologic detection.
Introduction
Rift Valley fever Virus (RVFV) (family Bunyaviridae, genus Phlebovirus) is a segmented,
negative-stranded RNA virus and the causative agent of the vector-borne zoonotic disease, Rift
Valley fever (RVF). The initial outbreak of RVF occurred in 1931 in the Rift Valley of Kenya in
sheep, cattle and humans [1]. Currently, RVFV is considered endemic across Africa fromMau-
ritania and Senegal in the west, Mozambique, South Africa and Namibia in the south, and
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north into Egypt and the Sinai peninsula [2]. The spread outside the African continent was
likely related to trade of livestock and presence of competent vectors [3, 4]. Implicit to the
transmission of RVFV are three genuses of mosquitos, Aedes, Culex, and Anopheles [5–7].
Importantly, the natural range of at least one of these vectors, Aedes, has expanded from tropi-
cal regions in south China and Indian Ocean Islands to other tropical and temperate zones in
all continents, due to the passive transport of viable eggs and subsequent adaptation (reviewed
in [8]). In addition, alterations to the global climate, as well as local forestation, development
and biodiversity, likely to play significant roles in expanded vector range, habitat and density
[9, 10]. RVFV outbreaks have had significant health, social and economic consequences,
requiring considerable expenditure of resources to interrupt the infectious cycle, monitor sus-
ceptible populations and treat exposed individuals. An outbreak of RVF in a developed country
or densely populated (people or livestock) region would be expected to have major health, eco-
nomic and social impacts, as livestock movement would be severely limited, and affected ani-
mals quarantined or culled, and human populations would have high morbidity with variable
levels of mortality [8, 11].
While susceptibility of naïve individuals to RVFV infection is high, protection can be
achieved by humoral immune responses or colostrum [12, 13]. In an outbreak scenario, great
energy, fiscal resources as well as human and animal lives could be saved with the single
administration of a vaccine that elicits rapid humoral responses and a long-term protective
immunity. Several vaccines have been developed to achieve this goal, including recombinant
RVFV protein vaccines, formalin-inactivated vaccines NDBR-103 and TSI-GSD-200 strains as
well as live-attenuated versions MP-12, Clone13 and various derivatives (reviewed in [14]). In
our previous work, we reported a rapid immune response with high serum neutralizing anti-
body titers as measured by the plaque reduction neutralizing test (PRNT80), and a strong long-
term immune response measured by a RVFV antigen-specific IgG enzyme-linked immunosor-
bent assay (ELISA) induced by authentic recombinant MP-12 (arMP-12) in both pregnant
sheep and cattle [15–17]. In 2014, arMP-12-NSm21/384 vaccinated sheep demonstrated excel-
lent protection against development of RVFV viremia and fever after a single dose when chal-
lenged with wild type ZH501 RVFV four weeks post vaccination [18, 19].
Recent studies assessing vaccine protection have gone beyond the traditional serologic anal-
ysis and employed transcriptomic sequencing techniques and bioinformatic analyses to better
characterize and understand the molecular and genetic underpinnings of the vaccine response.
A seminal work from Querec et al. assessed the transcriptome of CD8+ T and B cells from
humans vaccinated with the Yellow Fever vaccine YF-17D by microarray and identified a gene
expression pattern correlating to seroconversion [20]. Efforts were made to analyze the
immune response to influenza vaccination that identified not only high resolution molecular
signatures at 7-days post inoculation, but also identified gene signatures to predict antibody
response [21]. A meticulous serologic, cellular and bioinformatic analysis of pre–and post–vac-
cination samples from influenza vaccinates identified correlative biomarkers for vaccine
response quality in pre–vaccination samples [22]. Strides have been made in understanding
vaccine response in the veterinary sciences using transcriptome sequencing techniques also. In
response to vaccination againstMycobacterium bovis, cattle protection was highly correlated
with IFN-gamma and IL-22 expression [23].
To further our understanding of the genetic and cellular mechanisms underlying vaccina-
tion and seroconversion in arMP-12 vaccinated livestock, we hypothesized that bioinformatic
analysis of the RNASeq sequenced transcriptome of peripheral blood mononuclear leukocytes
(PMBC) will identify highly correlated gene transcripts for protective seroconversion as mea-
sured by PRNT80. To test this hypothesis, we analyzed the global transcriptome of PBMCs
from cattle vaccinated with arMP-12 against RVFV before and after vaccination, followed by a
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bioinformatic correlative analysis between perturbed cellular pathways and serologic analysis
for protective immunity. To more completely utilize the data, we analyzed resulting RNASeq
sequences by: 1) standard day-by-day analysis oriented from the day of vaccination, or 2) a
time-shifted mechanism in which the time points were oriented around the day that each calf
had protective 1:80 serum neutralizing antibody titers. For both of these orientations, sequence
data from each time point were analyzed by standard differential gene expression analyses [S1
Text] and Dynamic Bayesian Gene Group Activation (DBGGA) methodology to identify both
perturbed cellular pathways and gene ontology (GO) terms [24]. Using the time-shifted data,
we then employed a two-step approach to build a Dynamic Bayesian Network to predictively
correlate gene/pathway perturbation patterns with immune response and 1:80 protective anti-
body titers. We identified specific highly correlated cellular pathways and constitutive genes
that were perturbed preceding protective seroconversion. These results contribute to a deeper
understanding of the underlying biology of protective vaccine immune responses, as well as
underscoring the utility of bioinformatic analysis of high-density sequence data to identify
transcriptomic precursors to protective seroconversion.
Materials and Methods
Vaccine Strain and Plaque Reducing Neutralizing Titer Assay
Retrospective RNASeq analysis was performed on PBMCs taken from five healthy 4–6 month
Bos taurus steer calves as described previously [15]. The calves were injected intramuscularly
or subcutaneously with 1x105 PFUs of authentic recombinant MP-12 (arMP12) virus in 1.0 ml
of phosphate buffered saline (Sigma) [15, 25]. The arMP-12 virus is genetically identical to the
live, attenuated RVF MP-12 vaccine, prepared by the Salk Institute, Swiftwater, PA, for the U.S.
Army Medical Research Institute of Infectious Diseases (USAMRIID) for use in humans under
an Investigational New Drug (IND) Application [17, 25]. Serum was collected to assess the
presence of serum neutralizing antibodies using a plaque reduction neutralization test
(PRNT80) as previously described [26]. PRNT80 values used in this work were calculated and
reported to assess the immunogenicity of the arMP-12 vaccine to produce neutralizing anti-
bodies in cattle [15].
RNA Isolation, Preparation and Sequencing
Whole blood was collected from vaccinated cattle at DAY 0–7, 10, 14 and 21 and immediately
mixed at a 3:5 (blood:buffer) ratio with RNALater (Invitrogen). Samples were stored at –20°C
until processing. To purify RNA, frozen samples were thawed at 37°C, centrifuged at 2000xG,
and supernatant discarded. Remaining cell pellets were subjected to two rounds of treatment
with Red Blood Cell Lysing Buffer per manufacturer’s instructions (Sigma). RNA from result-
ing cell pellet was initially extracted by Trizol (Invitrogen) followed by treatment with RNeasy
Kit with on-column DNase digestion (Qiagen). Purified RNA was quantified by spectropho-
tometry on a NanoDrop (Thermo, USA) and by electrophoresis with a BioAnalyzer 2100 (Agi-
lent, USA). Only samples with an RNA Integrity Number (RIN) greater than 8.0 were used for
RNASeq analysis.
All RNASeq sequencing was performed at the Texas A&M Genetics and Bioinformatics
Center following manufacturer’s instructions. cDNA was generated from RNA samples of suf-
ficient quantity and quality with Ovation RNA-Seq System (NuGen, USA), sheared by focused
ultrasound (Covartis, USA) and made into barcoded (multiplexed) libraries with Encore Rapid
Library System (NuGen, USA). Samples were quantified, diluted, pooled and re-analyzed with
a Bioanalyzer and loaded onto a Genome Analyzer II High-throughput sequencer (Illumina,
USA). Sequence data (fastq format) were transferred to Seralogix LLC (Austin, TX, USA) for
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bioinformatic analysis. All of the original data are available in the Gene Expression Omnibus at
the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/),
Accession #GSE71417.
Sequence assembly and locus gene annotation
Raw read post processing steps were performed using a computational pipeline (Seralogix,
LLC, Austin, TX) described in more detail in S1 Text. All fastq read files were checked for qual-
ity (base quality scores, adaptor contamination, duplicate sequences) using FastQC [27]. Filter-
ing of read data to achieve the best quality fastq files was performed using Trimmomatic [28]
tools to remove adaptor contamination, low quality leading and trailing reads, and to crop read
length to 73-bp determined to be the optimal length of high quality reads. The resulting post-
processed fastq read files were aligned to the bovine reference genome UMD3.1 [29] using
Bowtie2 [30]. Utilizing the BedTools Multicov function [31], the read alignment overlap counts
were mapped to reference sequence file in BED [32] genomic interval format. The bovine geno-
mic intervals were obtained from Ilumina’s Igenome [33] as ready-to-use reference sequences
and gene annotations. Multicov converts these mapped read counts to genomic regions that
define known genes and then outputs a gene reads count table file inclusive of all samples over
the complete time course.
Transcriptomic statistical differential expression analysis
The gene reads count table was imported into a database for further processing in a computa-
tional pipeline where DESeq [34] was employed to normalize the data and determine the time-
course differential gene expression between vaccinated and non-vaccinated calves. Only gene
loci with an expression level greater or equal to 7 counts (0.3 counts per million reads) across
at least one half of all 47 samples were included in the normalization and differential expression
analysis. At each locus, p-value and z-score statistical tests and fold change were computed to
determine significance of differential expression. To account for multiple hypothesis tests, a
false discovery rate (FDR) was calculated using the fdrtool, an R program [35]. Only differen-
tial expressions with a q< 0.05 were considered statistically significant.
Pathway and gene ontology analysis using Bayesian models
To identify differentially expressed genes, GO terms [36], or pathways [37, 38], we employed
the Dynamic Bayesian Gene Group Activation (DBGGA) method (Seralogix, LLC, Austin, TX)
that includes all observed genes within a group to determine the overall perturbation impact of
the gene set in comparison to baseline controls. DBGGA analysis was performed to determine
temporal signatures of canonical pathways (PW) and gene ontology (GO) groups in response
to the RFV vaccine post inoculation (p.i.) or pre-serum neutralization (pSN). DBGGA enables
the determination of which PW and GO groups are most perturbed (activated or repressed) in
one condition relative to another and which genes are the significant sources of the perturba-
tion (designated as “influential regulator genes” (IRG). The DBGGA scoring method relies on
posterior Bayesian network sampling and interrogation methods to measure a complete PW or
GO group perturbation and can determine a single gene’s influence in a gene set and transform
this influence measure (log-likelihood deviation) to a z-score test statistic (hereafter referred to
as the Bayesian z-score to depict its association with DBGGA scoring method). Unlike other
pathway analysis or gene set enrichment [39] methods based on classical statistical tools, this
method identifies gene regulatory relationships that are most involved in the context of biologi-
cally related genes and their interactions (the DBGGA influence score is not reliant on identify-
ing differentially expressed genes prior to PW/GO analysis). Additional information on the
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DBGGAmethod has been described previously [24, 40–44] and reviewed briefly in S1 Text,
Sections 1.0 and 2.0. Additionally, an alternative approach to pathway and GO analysis was
conducted employing the R package “GAGE” [45] for comparative purposes.
Pathway temporal signature correlation with the antibody response
We developed a sliding window correlation (SWC) procedure (written in MATLAB [46]) to
identify early pathway response signatures that correlate with the time course of the plaque-
reduction neutralization test (PRNT80) to later time points at the onset of protective immunity.
The SWC procedure measures the temporal trajectory correlation of a pathway or GO term
Bayesian z-scores and their associated gene Bayesian z-scores for an incremental series of three
time points to a fixed PRNT80 temporal response signature that is also comprised of three time
points surrounding the PRNT80 serum neutralization point. We elected to use three time
points as our sliding window to better capture the early temporal dynamics of PW/GO events
that may have direct correlation to the later serum neutralization temporal signature. Correla-
tion coefficients (R) were computed for sets of overlapping successive pathway, GO and their
gene scores across all time points represented by the sliding time window sets (time -6, -5, -4;
times -5, -4, -3; times -4, -3, -2;times -3, -2, -1; times -2, -1, 0; and times -1, 0, 1) with the fixed
PRNT80 temporal response at times -1, 0, 1 pre-serum neutralization that represents the onset
of protective immunity. Additional details of the sliding window correlation procedure and
definition of pre-serum neutralization time points are described in S1 Text, Section 3.0.
Learning transcriptomic temporal signatures to predict protective
immune response
Ideally, we sought to identify early patterns in the pathway and transcriptomic host responses
that can be used to predict protective immunity. We developed a dynamic Bayesian network
(DBN) modeling approach [47] to use as a predictive model of the PRNT80 protective immune
response from the highly correlated gene expression found present in a selected set of corre-
sponding SWC correlated pathways and GO terms. This is a supervised learning method that
can uniquely deal with time-course data. The method is described in greater detail in S1 Text,
Section 4.0
Ethics Statement
Healthy, 4–6 month old Bos taurus heifer and steer calves were used in the present study as
described previously [15]. The Texas A&M University Institutional Animal Care and Use
Committee approved the Animal Use Protocol 2010–192 in accordance with the U.S. Animal
Welfare Act as enforced by the United States Department of Agriculture, Animal and Plant
Health Inspection Service.
Results and Discussion
Read mapping and transcript gene annotation
RNA from whole blood was isolated from cattle [15] prior to vaccination (D0) as well as after
inoculation (D1-7, 10, 14, and 21) and analyzed by RNASeq. After demultiplexing of the
sequencing data, we obtained a range of total read counts across the 47 biological samples vary-
ing from 36 to 67 million single-end reads. After further processing for filtering and alignment,
we obtained a range across the samples from 31 to 53 million reads representing 76–89% of the
starting reads aligning to the reference bovine genome [48] indicating a high proportion of
mapped reads and a reasonable uniformity between samples (S1 Table). We then performed a
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mapping of reads to known genomic gene locations using the Igenome NCBI genomic interval
reference and the associated NCBI annotation file [33]. We obtained 16,787 genes, after filter-
ing for expression level threshold of at least 7 counts per loci across a minimum of 50% of the
individual samples. Only genes meeting these criteria were used for further analysis.
Standard-time differential expression resulting from vaccination
During the time course collection of our samples, we sampled most frequently on days imme-
diately following vaccination, as well as regular intervals out to 3 weeks post vaccination (D1–
7, 10, 14, and 21). This repeated sampling early in the experiment allowed for a more detailed
analysis of the gene expression profiles present just after vaccination, in contrast to analysis of
the transcriptome from a single time point post-inoculation, and provided for improved orien-
tation of transcriptome data to previously reported serologic data [15]. Plaque reducing serum
neutralizing titers (PRNT80) serve as an accurate indicator for protection against wild-type
RVFV and are commonly used in determining RVFV vaccine effectiveness [15, 16, 49–52]. S/
N analysis of five calves used for transcriptomic study identified an average protective titer of
1:80 by D11 p.i. (Fig 1A and 1B).
Differential gene expression was determined in conjunction with DESeq and resulted in a
time-course profile of significantly perturbed up and down regulated genes (Fig 1C). Differen-
tial expression levels in vaccinated animals were determined by comparing transcript levels to
their own baselines over the 21 day time-course (FDR<5%; |Z-score|2.24). Temporal change
in the number of significant expressions is more pronounced in the days prior to seroconver-
sion which occurred at between 10 and 21 days post inoculation. The top 15 up and down regu-
lated expressions by time are listed in S2 Table with a more complete gene description list
provided in S3 Table.
Dynamic Bayesian Gene Group Activation (DBGGA) Pathway Analysis
Employing the DBGGA process, 229 pathways and 4127 unique genes were scored in this
KEGG pathway set. The term pathway is used broadly as defined by KEGG and may include
other gene sets that may define, for example, protein interactions or disease networks that are
not strictly considered as signaling or metabolic pathway network types. The summary results
of activated and repressed pathways and the up-regulated and down-regulated genes meeting a
|Bayesian z-score|> 2.24 are shown in Fig 2A (full list of DBGGA Pathways in S4 Table; full
list of genes from identified in DGBBA Pathways in S5 Table). Activation or repression is
determined by the overall numeric average of the DBGGA Bayesian z-score for all associated
genes within a pathway. If the average is positive, indicating the dominance of up-regulated
genes, the overall pathway score is designated as activated, else if the average is negative the
pathway is designated as repressed and the pathway score is annotated accordingly with a plus
or minus sign. Since our time course covers immunologically distinct periods, we expect dis-
tinct pathways and genes to be perturbed at different points after vaccination. To better capture
these variations, we grouped the time points into “Early Phase” (D2–6) and “Late Phase” (D7,
10, 14, and 21). In the Early Phase, there were 10 activated pathways, with the most notable
being phosphatidylinositol signaling system, apoptosis,Wnt signaling pathway, VEGF signaling
pathway, Jak-STAT signaling pathway and ErbB signaling pathway (Fig 2B). The most
repressed pathways included chemokine signaling,MAPK signaling, ribosome, focal adhesion,
and toll-like receptor. Interestingly, the ribosome pathway was significantly down-regulated
throughout the course of the study, an expression pattern that was previously seen in cattle vac-
cinated against Bovine Viral Diarrhea Virus and hypothesized to be apart of a coordinated host
response for down-regulation of protein synthesis during viral infection (Fig 2B) [53]. While
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the specific contribution of genes comprising the ribosome pathway to immune response to
arMP-12 is unclear, this characteristic may be an important global gene regulation feature for
immune response against viral infection.
At Day 7 in the Late Phase, there were only 5 significantly perturbed pathways meeting a |
Bayesian z-score|> 2.24, which is in high contrast to that of day 10 where 100 were perturbed.
We also observed that day 10 had the highest number of differential expressed genes. Since the
DBGGA pathway scoring method is very sensitive to changes in the gene expression in the
experimental condition, the higher perturbation in the number of genes reflects this larger
number of pathway perturbations. This increased perturbation at day 10 was mainly attributed
to increases in metabolic, organismal systems, and human disease pathways, which may not be
directly related to the vaccine immune response.
While the pathways perturbations from the Early and Late Phases provided insight into the
molecular and genetic underpinnings of immune response to vaccination, the authors note
that it was beyond the design of this retrospective study to deduce specific causative effects
Fig 1. Serologic and perturbed gene analysis of cattle vaccinated with arMP-12. (A) Log10 plaque
reducing neutralizing titers (Log10(PRNT80)) of test animals prior to and after vaccination with arMP-12. A
dilution of 1:80 (log10 = 1.903) was used as the cutoff to determine protection fromWT RVFV challenge
based on prior published work. (B) Schematic of the immunologic status of test animals by day of experiment:
unvaccinated (gray), vaccinated, below PRNT80 cutoff (light red), vaccinated, first day at or above PRNT80
cutoff (dark green), vaccinated, above PRNT80 (light green). (C) Summary count of significantly perturbed
genes normalized against unvaccinated samples occurring in at least 50% of animals by day post inoculation,
with a |Z-score2.24| and a false discovery rate (FDR)0.05.
doi:10.1371/journal.pone.0147027.g001
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between the arMP-12 vaccination, the immunologic response as observed by RNASeq, and
generation of neutralizing antibodies. Several perturbed pathways noted in Fig 2 have no obvi-
ous specific link to immune response, such as Neurotrophin signaling pathway or Gap junction.
We speculate that these pathways share constitutive perturbed genes with pathways more
directly related to immune response. While there may be a tangential or parallel activation of
these pathways as a result of vaccination or generic immune response, we have not fully investi-
gated this possibility in this work.
DBGGA gene ontology (GO) term analysis
The DBGGA process scored 4354 biological process GO Terms (restricted to GO terms having
between 5–300 observed genes within a given term). Within this set of GO Terms, there were
6818 uniquely scored genes. The summary results of activated and repressed GO Terms and
their associated gene sets are shown in Fig 3A. A complete list of perturbed GO Terms and
their associated DBGGA gene scores are provided in S6 and S7 Tables, respectively. In the
Early Phase, a set of relevant activated and repressed GO Terms were selected to show the com-
plex dynamics of the early host innate immune response to arMP-12 vaccine (Fig 3B). There
were GO Term perturbations associated with regulation of RIG-I signaling pathway, positive
regulation of interferon-alpha, cellular response to interferon-gamma, response to interferon–
alpha and–beta, viral protein processing, viral transcription, and viral life cycle. RIG-I signaling
Fig 2. Dynamic Bayesian Gene Group Activation (DBGGA) Pathway analysis. (A) Summary table of cellular pathways significantly activated or
repressed (Bayesian score|2.24|) over the time course of the experiment as determined by the DBGGA tool. (B-C) Read out and heat map of significantly
perturbed pathways during days post inoculation (p.i.). Red color indicates activation, green color indicated repression. Intensity of color represents
amplitude of perturbation. Analyses are oriented to the Early Phase (days 2–6 p.i.) (B) or the Late Phase (days 7, 10, 14, 21 p.i.) (C) to identify significant
perturbations at different periods during the vaccine response.
doi:10.1371/journal.pone.0147027.g002
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activation is likely caused by the detection of pathogen-associated molecular patters (PAMP)
within the vaccine viral RNA and initiates the innate antiviral immune response, an essential
precursor for launching an effective adaptive immune response. Viral life cycle and viral tran-
scription are highly repressed GO terms with 72 genes being significantly down-regulated in
the early phase. The majority of these genes encode for ribosomal proteins. The viral process
GO terms are associated with processes by which a viral gene is converted into a mature gene
product or products (proteins or RNA). This includes viral transcription, processing to pro-
duce a mature RNA product, and viral translation indicating viral replication. The dominant
genes involved in these processes included 54 genes encoding a family of ribosomal proteins.
These important GO terms and associated genes are listed in S6 and S7 Tables respectively.
Also provided in S6 Table and show in Fig 3B are details of other important early phase
highly repressed GO terms that include antibacterial humoral response, positive regulation of B
cell receptor signaling, positive regulation of macrophage cytokine production, and negative regu-
lation of MHC class II biosynthetic processes. Interestingly, of these repressed GO terms only
Fig 3. Dynamic Bayesian Gene Group Activation (DBGGA) Gene Ontology (GO) Term analysis. (A)
Summary table of significantly perturbed GO terms and genes described by day post inoculation. Only GO
terms and their genes with Bayesian score|2.24| are included in analysis. (B-C) Heat maps of perturbed
GO terms described by day post inoculation (p.i.) and identified from the Early Phase (B) and the Later Phase
(C). Red color indicates activation, green color indicates repression. Intensity of color represents amplitude of
perturbation. The list of GO terms shown represents a subset of all perturbed terms that were selected as
being most relevant to innate and adaptive immune response.
doi:10.1371/journal.pone.0147027.g003
Gene Expression in Vaccine Response
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the positive regulation of B cell receptor signaling becomes significantly activated in the later
phase (defined to include days 7, 10, 14, and 21). Also in the early phase, we observed the
strong activation of such biological processes as the interleukin-1beta, 17, and 18 production,
regulation of Fc receptor mediated stimulatory signaling, intrinsic apoptotic signaling by p53
class mediator, negative regulation of leukocyte mediated cytotoxicity, regulation of cytokine pro-
duction, clathrin-mediated endocytosis,[54] and positive regulation of natural killer cell
differentiation.
In the Late Phase, we began to detect more biological processes associated with the adaptive
immune response which included T cell activation, differentiation, and receptor signaling, regu-
lation of T-helper cell differentiation, B cell activation, regulation and receptor signaling, and
regulation of memory T cell differentiation, T-cell differentiation, T-helper 1 type immune
response, immunoglobulin mediated immune response, and regulation of T cell cytokine produc-
tion (Fig 3C). By Day 21, the host response returned to a basal state, as seen in the reduction in
number of perturbed GO Terms and associated genes (Fig 3A). As before, we note that this ret-
rospective analysis is unable to differentiate between a specific response to arMP-12 vaccina-
tion and a generic immunological response. We expect many of the perturbed genes pathways
identified in this analysis would be found in either an infectious challenge with wild-type Rift
Valley fever Virus or possibly other pathogenic viral insults due to the current understanding
of these pathways in viral immune response. Despite this, we propose that these data provide
an important baseline of temporal immune response that will aid in future vaccine develop-
ment, therapeutics, and diagnostics.
Defined time-shift analysis of differential gene expression data
With out-bred animal subjects, variation in the immune response to vaccination is expected. In
this experiment, the time for PRNT80 to reach the threshold of 1:80 PRNT80 (log10 = 1.903
indicated by horizontal dotted line) for calves #74 and 76 was D10 after inoculation (Fig 1B).
However, in this animal cohort, calves #75, 86, and 88 reached their 1:80 threshold at D14 (Fig
1B). While this difference has minimal impact on determining the efficacy of the vaccine, the
delay may effectively mask the true genetic and mechanistic response preceding the production
of neutralizing antibodies. A day-by-day analysis of an asynchronous genetic response could
fail to accurately identify perturbed pathways or genes, or obscure important expression trends
and perturbations.
To account for this, we performed a defined time-shift analysis by synchronizing the
sequence data from each animal to reflect the antibody response (Fig 4A and 4B). We shifted
the sequence data to align all animals by the time point when the serum neutralization titers of
each animal reached clinically protective levels at a 1:80 PRNT80 titer [15, 50, 55]. We achieved
alignment by shifting calves # 75, 78, and 88 to align their time of serum neutralization with
calves # 74 and 76. Data in this time-shifted orientation are reported as time prior to serum
neutralization (pSN), with the time point of seroconversion labeled as Time 0 and relative per-
turbation determined by comparison to pre-vaccinated samples.
As with the standard time data, differential gene expression was determined by bioinfor-
matic methods and DESeq. A time course analysis of perturbed genes (FDR<5%, |Z-score|
2.24) showed a steady increase of both up and down regulated genes from –6 pSN until –2
pSN, after which there was a rapid drop in number of perturbed genes for the remaining time
points (Fig 4C). The top 15 up or down regulated genes are listed in S8 Table, and a complete
perturbed gene list is provided in S9 Table. Several up and down regulated genes are common
to the Early or Late Phases from both the standard-time and time-shifted data sets, including
tumor necrosis factor super family 10 (TNFSF10), gamma-interferon-inducible protein Ifi-16
Gene Expression in Vaccine Response
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(IFI16), the gene coding for B-cell linker protein (BLNK), and lymphocyte-specific protein 1
(LSP1). In both time treatments of the data, numerous ribosome family proteins were among
the most down-regulated genes in the Early Phase (see S10 Table for comparison).
Defined Time-shifted DBGGA pathway analysis
The summary results of activated and repressed pathways and the up-regulated and down-reg-
ulated genes meeting a |Bayesian z-score|> 2.24 are shown in Fig 5A (full list of pathways in
S11 Table, list of genes in S12 Table). Since these time-shifted data use the same original data
as the standard time analysis, the same number of signaling/metabolic pathways (229) and
unique genes (4127) were observed here as before. We have again segregated the data into
Early Phase (time –6, –5, –4, and –3, pSN) and Late Phase (–2, –1, and 0 pSN) to better appre-
ciate the genetic components active at each phase of the immune response.
The majority of significantly modulated pathways was repressed, especially at in the Early
Phase (–6, –5, and –4 pSN). At very early and late time points, Phosphatidylinositol signaling
Fig 4. Serologic and perturbed gene expression in time-shifted data. (A) Log10 plaque reducing
neutralizing titers (Log10(PRNT80)) of test calves prior to and after vaccination with arMP-12 with data
synchronized to the time point that each animal reached the minimum threshold (T = 0; 1:80, log10 = 1.903).
(B) Schematic illustrating the immunologic status of test animals in time shifted analysis: unvaccinated (gray),
vaccinated, below PRNT80 cutoff (light red), vaccinated, first day at or above PRNT80 cutoff (dark green),
vaccinated, above PRNT80 (light green). (C) Count of significantly perturbed genes normalized against
unvaccinated samples occurring in at least 50% of animals by time pre-serum neutralization, with a |Z-score
2.24| and a false discovery rate (FDR)0.05.
doi:10.1371/journal.pone.0147027.g004
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was significantly perturbed (Fig 5B and 5C). Several viruses have been shown to modulate the
Phosphatidylinositol signaling system [56–58]. Recent findings suggest that in response to dou-
ble-stranded RNA (dsRNA), the phosphatidylinositol-3-kinase (PI3K) is activated and medi-
ates activation of the transcription factor interferon regulatory factor 3 (IRF3) [56]. Gene level
analyses of this pathway indicated that the most prevalent up-regulated PI3K related genes
across most time points were PIK3R1, PIK3R2, PIK3R3, PIK3C2B, and PIK3CA, but the gene,
IRF3, was only notably up regulated in the TLR pathway at times –6 and –1 pSN (S9 Table).
Phosphatidylinositol signaling has also been implicated in the activation of Calcium signaling
and more specifically the Ca2+/calmondulin kinase. PI3Ks are known to regulate diverse sig-
naling pathways involved in growth, proliferation, survival, differentiation and metabolism. In
T cells, PI3Ks can be activated by a number of different receptors including the T cell receptor
(TcR), co-stimulatory receptors, cytokine receptors, and chemokine receptors.
In comparing the standard time and time-shifted DBGGA pathway analyses, several path-
ways were detected by both treatments. In the Early Phase, Phosphatidylinositol signaling sys-
tem, Jak-STAT signaling and ErbB signaling pathways were identified as up-regulated by both
analyses (Fig 2 vs. Fig 5; S4 and S5 Tables vs. S11 and S12 Tables). Within the Late Phase, the
standard analysis identified numerous highly perturbed, up-regulated pathways, while the
Fig 5. DBGGA pathway analysis on time-shifted data. (A) Summary table of significantly activated or repressed cellular pathways (Bayesian score|
2.24|) on time shifted data. Perturbation of cellular pathways and constituent genes are reported. (B-C) Heat map representation of significantly perturbed
pathways at times pre-serum neutralization (pSN). Red color indicates activation, green color indicates repression. Intensity of color represents amplitude of
perturbation. Analyses are oriented to the Early Phase (time –6, –5, –4, –3 pSN) (B) or the Late Phase (time –2, –1, 0, 1 pSN) (C) to identify significant
pathway perturbations at different periods during the vaccine response.
doi:10.1371/journal.pone.0147027.g005
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time-shifted analysis detected just 13 up-regulated pathways. We found this to be an important
difference between the treatments of the time course data, as the time-shifted analysis
decreased the number of perturbed pathways, allowing for a more focused list of high priority
pathways for further examination. In this case, the time-shifted analysis identified immunolog-
ically relevant pathways Fc gamma R-mediated phagocytosis, B cell receptor signaling pathway,
Phosphatidylinositol signaling system, andWnt and ErbB signaling pathways.
Defined time-shifted DBGGA gene ontology (GO) term analysis
As before, the DBGGA process scored 4354 biological process GO terms (restricted to GO
terms having between 5–300 observed gene within the term). Within this set of GO terms,
there were 6818 uniquely scored genes. The summary results of activated and repressed GO
term gene sets only for GO terms of root “biological_process” are provided in Fig 6A. A set of
noteworthy activated and repressed GO terms were selected (Fig 6B, S13 Table), to show the
dynamics of the host response to MP-12 vaccine. There was a considerable change over the
time course between days indicating a very diverse response. At time– 6 pSN, two highly acti-
vated DBGGA GO terms were response to interferon-alpha (GO:0035455), response to inter-
feron-beta (GO:0035456), negative regulation of viral genome replication (GO:0045071),
Fig 6. DBGGAGO term analysis on time-shifted data. (A) Summary table of GO Terms and component gene perturbation by time pre-seroconversion.
Only GO terms and their genes with Bayesian score|2.24| are included in analysis. (B-C) Heat maps of perturbed GO terms described by time pre-
seroconversion and identified from the Early Phase (time –6, –5, –4, –3 pSN) (B) and the Later Phase (time –2, –1, 0, 1 pSN) (C). Red color indicates
activation, green color indicates repression. Intensity of color represents amplitude of perturbation. The list of GO terms shown represent a subset of all
perturbed terms that were selected as being most relevant to innate and adaptive immune response.
doi:10.1371/journal.pone.0147027.g006
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positive regulation of T cell cytokine production (GO:0002726), and positive regulation of inter-
leukin-1 beta production (GO:0032731), reversing and becoming repressed in later time points.
This emphasis on pathways associated with the Type-I interferons may serve as an
important factor in distinguishing vaccinated and infected animals. During a vaccine trial with
mutagenized or gene deletion strains of the virus on mice lacking interferon (IFN)–alpha/beta,
or–gamma receptors, vaccine strains elicited strong IFN–alpha and–beta responses while the
WT control strain failed to elicit the same response [59]. Follow-up work with a deletion
RVFV strain showed the non-structural protein NSs was responsible for blocking expression of
IFN by targeting a basal cellular transcription factor [59–61]. The strong IFN expression identi-
fied in this study with the MP-12 vaccine suggests the known V160A mutation in the NSs, or a
combination of mutations in MP-12 including NSs, is sufficient to compromise the normal
repressive functions of the protein in cattle [14].
In comparing the DBGGA GO term analysis between standard time and time-shifted data,
there is a typical down regulation of GO Terms and genes, with the most perturbation at D10
for the standard time (Fig 3A vs Fig 6A). With the time-shifted data, the general trend of down
regulation at each time point remains consistent with the standard time, however the number
of perturbed GO terms is generally lower and peaks at time –3 pSN (Fig 6A).
In the Early Phase, the standard time data identified numerous perturbed pathways associ-
ated with immune response, including viral transcription, several pathways involved with inter-
feron alpha or beta production, and interleukin-1 production and response. As before, this
analysis resulted in a large cohort of perturbed pathways. Under the time-shifted protocol, the
overall number of perturbed pathways was decreased in both the Early and Late Phases, but
immunologically relevant pathways were still detected. Of note was the down regulation of
viral transcription, protein processing, and life cycle pathways and up regulation of pathways
associated with interleukin-1 and response to interferon alpha.
Pathway and GO term temporal signature that correlate with the PRNT80
response
To gain insight into the potential mechanisms underlying the host response to the arMP-12
vaccine and to elicit early biomarkers of protective immunity, we developed a sliding window
correlation (SWC) approach to apply to pathways, GO terms, and genes (Fig 7, S15 Table). We
choose the log(PRNT80) time points of days –1, 0, and 1 pSN to represent the onset and estab-
lishment of protective immunity (see Figs 4A and 7A-i). This trajectory of data over the three
time points was correlated against the pathway, GO term, and gene DBGGA scores obtained
for each host across all time points post immunization.
The SWC analysis included only the canonical pathways with the exclusion of metabolic
pathways. Fig 7B-i lists the pathways by time window for those found to meet a significance-
of-correlation |p-value|< 0.05 and with pathway scores at any one time point exceeding the |
Bayesian z-score|> 2.24. The p-values are given a sign to indicated positive (+) or negative (-)
correlation direction. Note also that time windows (Times –6, –5, –4 pSN and –5, –4, –3 pSN)
are all negatively correlated while for the time windows (Times –3, –2, –1 pSN) and beyond are
all positively correlated.
Likewise for the Gene Ontology GO terms, we applied the SWC technique to obtain the
most highly PRNT80 correlated terms for which the results are listed by the sliding window
time points (Fig 8). With the more focused gene sets that comprise the GO terms, we observed
stronger correlation values and more immune related terms. For example, we detected strong
correlation of viral related biological processes such as viral protein processing (GO:0019082),
viral life cycle (GO:0019058) (see correlation plot Fig 8B, upper graph), viral transcription
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(GO:0019083), and viral release from host cell (GO:0019076). Additionally, we observed early
indicators of the host immune response with the correlation of PRNT80 with the biological pro-
cesses such as cellular response to interleukin-4 (GO:0071353), interleukin-1 beta production
(GO:0032611), negative regulation of B cell activation (GO:0050869), and type I interferon sig-
naling pathway (GO:0060337).
To narrow the search space for genes that were candidate biomarkers of protective immu-
nity, we selected the sets of genes for pathways and GO terms having significant correlations
from 19 relevant pathways and processes (Fig 9A). The SWC technique identified 145 unique
highly correlated genes as listed in S15 Table. A subset of most highly correlated and relevant
genes is listed in the table of Fig 9B. There was a dominance of genes encoding a large family of
ribosomal proteins that were overlapping across the biological processes that included viral life
cycle, SRP-dependent co-translational protein targeting to membrane, viral protein processing,
viral release from host cell, and ribosome pathway. Accordingly only a few of these gene types
were represented in the table. Interestingly, the ribosomal genes were among the highest SWC
correlated relationships to occur at the earliest time window (Times –6, –5, –4 pSN). Also of
Fig 7. Sliding window correlation (SWC) to identify pathways associated with serum neutralization titers. (A) Visualization of sliding window
correlation approach. (i) Hypothetical Log10(PRNT80) data taken from time points capturing neutralizing antibody levels during time period in which animals
reached threshold for protection (log10 = 1.903) (dark green bars). (i-ii)The trajectory of the Log10(PRNT80) data is applied to other time points prior to serum
neutralization (light green bars) to identify pathway with complementary or antithetical trajectories (A-ii for hypothetical Pathway Bayesian Z-score data, dark
blue bars). (iii) Graphical representation of the R correlation coefficient value between Log10(PRNT80) and Pathway Bayesian Z-score. (B) Pathways
correlated to PRNT80 values at the time of seroconversion listed by pathway at incremented window times (each consisting of three time points), with
significant correlation p-values (i), or plotted as log(PRNT80) vs normalized Bayesian Z-score (ii) for six selected pathways having highest correlations.
doi:10.1371/journal.pone.0147027.g007
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note, many of the genes in the first two time windows are negatively correlated, but interest-
ingly, the genes PIK3R5, SOCS5, PLCE1, and GHR were positively correlated. The majority of
genes in the remaining time windows was positively correlated. It was also observed that the
later time windows (Times –5, –4, –3 pSN and Times –4, –3, –2 pSN) had a reduced number of
correlated genes and weaker significance (p-values) of correlation.
Dynamic Bayesian Network (DBN) predicts protective immunity
The SWC analysis identified a set of genes associated with certain pathways and GO terms (See
Table 1). A set of correlated genes associated with PRNT80 response was insufficient on their
own for building a predictive model, since it should be constructed based on biologically rele-
vant relationships and cascade of events. There were other relationships both upstream and
downstream from these genes that may have critical roles in defining transcriptional events
leading to a protective immune response. It was this set of biologically related genes of the
innate immune response that are of prime interest, and hence were used to create a DBN
model. We employed a two-step approach to constructing a predictive DBN. The first step
employed a novel approach to learning a gene regulatory network (GRN) structure that is
described in more detail in S1 Text Section 4.0. In this approach, the starting point is to seed
the learning algorithms with a starting set of genes, which in our case were the genes associated
with perturbed pathways that had the majority of temporal correlated gene expressions to
PRNT80 found by the SWC analysis. These pathways included the Toll-like receptor, Jak-STAT
signaling, RIG-I-like signaling, Fc gamma R-mediated phagocytosis, Calcium signaling, Antigen
Fig 8. Sliding window correlation (SWC) to identify GO terms associated with serum neutralization titers. (A) Immunologically important GO terms
correlated with log10(PRNT80) listed by time window with associated p-value indicated significance of correlation. (B) Correlated GO terms plotted as log10
(PRNT80) vs Normalized GO term DBGGA Bayesian z-scores. The GO term Viral life cycle had a negative correlation with seroconversion at the windowed
time points –6, –5, and –4 pSN (upper panel), while Positive regulation of T cell cytokine production shows a positive correlation with seroconversion at the
windowed time points –4, –3, and –2 pSN (lower panel).
doi:10.1371/journal.pone.0147027.g008
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processing and presentation, selected ribosomal genes from viral life cycle, and included genes
with type I interferon activation.
The GRN method used a Bayesian model consensus scheme employing the Markov Chain
Monte Carlo (MCMC) Metropolis-Hastings algorithm. It incorporates a gene expression data-
derived proposal matrix and a priori probability distribution method for combining prior bio-
logical knowledge from multiple sources that included KEGG [37], REACTOME [62], Bio-
GRID [8], DIP [63], IntAct [64], MINT [65], GO, and predicted and known transcription
factors (TF) binding sites from TRANSFAC [66] and JASPER [67]. For the second step, the
output of the GRN provided a unique approach to identifying high probability relationships
between the highly correlated genes and other upstream and downstream genes. The GRN
identified correlated genes and their relationships to other genes in which the relationships
were found through either known canonical relations, predicted based on protein domain
binding likelihood, sequence similarity to know binding domains, or through transcription fac-
tor binding. Through this technique, we narrowed the choice of DBN model genes to 50
employing a selection method that focused on SWC genes and their upstream and/or down-
stream GRN learned relationships that resulted in the selection of cell receptors, signaling pro-
cessing, and gene end products. The complete descriptions of these 50 genes are provided in S9
Table. By interrogating the GRNmodel for key regulatory relationships, we found strong
Fig 9. Summary of DBGGA Pathways or GO terms and constituent genes with high correlation to protective antibody response. (A) A selected set
of DBGGA scored pathways or GO terms most correlated with protective antibody response employed for learning the dynamic Bayesian network model for
inferencing future protective immune response. (B) A subset of immunologically relevant genes associated with pathways and GO terms listed in (A) that are
highly correlative to serologic protection as determined by PRNT80. Various time windows are represented, with time –6, –5, –4 pSN window being the
furthest from the designated time of serologic protection.
doi:10.1371/journal.pone.0147027.g009
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supporting evidence that upon vaccination, the vaccine RNA could be recognized by the Toll-
like Receptors (TLR), or more specifically, TLR4, a negative SWC correlate to PRNT80
response. Expression of other specific genes having learned relationships downstream of TLR4
were found to include MYD88, MAP2K7, IL1B, FOS, and JUN, where FOS and JUN form the
well-known transcription factor complex AP-1. TLR mediated signaling pathway predomi-
nately signal through interferon regulatory factors (IRF) as well as Nuclear Factor-kappa B
(NFKB) and AP-1, eliciting the induction of the Interferon type-1 response and the expression
of inflammatory cytokines. In support of interferon activation, GRN learning identified
IFNAR1/2 and IFNGR1/2 as influential regulators in the GRN model. These genes encode pro-
teins that function as antiviral factors. We found IFNAR2 to be a positive SWC correlate to
PRNT80, and through our GRN learning, we found evidence supporting an activation relation-
ship with STAT1 and a STAT1 relationship with the cytokines CISH and SOCS2.
In addition, we found other type I interferon associated GRN model genes that included
MYD88, JAK2, SOCS2/5, CCL5, IL8, IL15, IL12RB1, and IRF9. The genes MYD88, SOCS2,
IL8 and IL15 were negative SWC correlates to PRNT80 response while IL12RB1, JAK2 and
SOCS5 were positive correlates. Also found by GRN learning was the gene, SYK, which is criti-
cal to innate and adaptive immunity having strong evidence regulating the downstream gene,
PIK3R3, which is a positive SWC correlate to PRNT80 response. Also, the RIG-I-like receptor
related genes, IFIH1 and DDX58, were identified by the GRNmodel as strong regulators. How-
ever, these genes were not found to be SWC correlates, but were significantly expressed and
indirectly linked to other SWC correlate genes such as TBKBP1 and IL8. IFIH1 and DDX58
genes are known to encode for proteins of the RIG-I-like receptor family and functions as pat-
tern recognition receptors that sense viral nucleic acids or other viral/vaccine products.
The genes ERBB4 and ADORA2B (positive and negative SWC correlates to PRNT80 respec-
tively) were found to be important receptors and perhaps novel to the correlated response to
RVF vaccine. ERBB4 encodes a protein that is a receptor for neuregulins and EGF family mem-
bers and is known to regulate cell proliferation, differentiation, migration and apoptosis.
ADORA2B encodes a G-protein receptor and is known to inhibit monocyte and macrophage
functions and stimulate mast cell mediator release. GRN learning found ERBB4 to have strong
relationships with PLCB1 and PLCE1 that is a positive SWC correlate. PLCE1 belongs to the
phospholipase family involved in the cascade of intracellular responses that result in cell
growth and differentiation. GRN learning associated ADORA2B with the downstream genes
GNAL, ADCY7, PRKX and ATP2B2 are positive SWC correlates to PRNT80 response suggest-
ing a novel role as correlates to protective immunity. Vaccine viral replication and expression
were strongly indicated in the early phase post immunization. Numerous genes encoding for
ribosomal proteins were SWC correlates to PRNT80. We chose four of the most highly corre-
lated to include in the DBN model, namely, RPS14, RPL14, RPL29 and RPLP2.
In the later times (Times –4, –3, –2, –1, 0 pSN) where the time begins to overlap with the
onset of serologic protective response, there were fewer SWC correlates to PRNT80. Interest-
ingly, antigen processing and presentation stood out to have several later phase PRNT80 corre-
lates with the genes CD4, CD8B, CTSB. CD4 is a T-cell surface glycoprotein on T lymphocytes
and also in B cells and macrophages. CD4 is thought to be associated with T-cell activation.
GRN learning found relationships with three forms of Major Histocompatibility Complex,
class II genes, namely, BOLA-DQB, BOLA-DQA1, and BOLA-DRB3, all are expressed on anti-
gen presenting cells (B lymphocytes, dendritic cells, macrophages). CD8B is a CD8 antigen
found on most T lymphocytes. CTSB is a gene encoding a lysomomal cysteine proteinase
believed to participate in intracellular degradation of proteins. The description of these genes
and function is provided in S16 Table.
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Employing the majority of these genes described above, the DBN model was constructed to
represent three early phase time points (T = –5, –4, and –3) pSN, but included the later
PRNT80 data time points (T = –1, –0, and 1 pSN) for training the model to be predictive for
these later PRNT80 time point responses. The DBN network is illustrated in Fig 10A. Each gene
and PRNT80 node represents a continuous variable having Gaussian distribution.
The goal of the DBN model was to determine if gene expression evidence at earlier time
points could robustly predict/infer a protective PRNT80 response at later time points. With
limited sample size, we could only train and test the predictive response with gene expression
evidence from five biological replicates at three distinct time points (Times –5, –4, and –3
pSN). Cross-validation and blind prediction were not feasible and are planned for future
research validation efforts. We implemented a t-test statistic to test when an inferred PRNT80
value was determined to be statistically outside the experimental (true) mean population
(p 0.05) for use in sensitivity analysis. Expression data for the true gene sets were used for
the true positive test cases which consisted of individual time point data sets of the three time
points and five biological replicates. A randomly selected set of gene expressions were used to
create a test set to represent the true negative test cases. The predicted PRNT80 plot, Fig 10B,
and model performance table, Fig 10C, illustrates the robustness of the resulting model.
Conclusions
Understanding the mechanisms underlying the development of protective immunity against
RVFV, and RVF vaccination, will be important for the development of more effective vaccines
against RVF. Host genome-wide transcript abundance and signaling pathway profiling pro-
vides a means to identify changes in gene expression and biological function occurring imme-
diately following vaccination that may play a role in the development of protective immunity.
Fig 10. Prediction of protective immunity by the Dynamic Bayesian Network (DBN). (A) The Dynamic Bayesian network model representing the
learned gene regulatory network structure. Each node represents a continuous variable with a Gaussian distribution. The DBN was trained with the time
course data associated with each gene. Relationships between gene nodes, or between the gene node and the PRNT80 node, are represented by arrows as
a directed acyclic graph. (B) Example inferencing results on a selected set of gene expression data taken at time window -5, -4, -3 pSN to predict the PRNT80
outcome. Graph indicates strong serologic response and log10(PRNT80) levels sufficient for protection given hypothetical gene expression data. (C)
Performance table for model experiment in (B) show high specificity and sensitivity of the model predictions in a time window up taken at –5, -4, -3pSN. Data
sets for true negative testing were randomly selected from other genes at the same time points as the true positive gene data sets. Data from five individual
animal subjects were employed for the model evaluation.
doi:10.1371/journal.pone.0147027.g010
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Here, we used the hypothesis that bioinformatic analysis of deeply sequenced peripheral blood
mononuclear leukocytes (PMBC) transcript will identify highly correlated gene transcripts for
protective seroconversion as measured by PRNT80. This approach has revealed transcriptomic
signatures underlying the host response to vaccination with arMP-12, as well as a distinct set of
genes that would be expected to be predictive of a protective immunological response.
There were 1587 unique genes differentially regulated following immunization by arMP-12,
of which 678 were uniquely up regulated genes compared to 909 uniquely down regulated.
Consistent with other previously reported gene expression results in the mouse model infected
with RVFV [68], the larger number of down regulated genes is likely a reflection of the high
amount of arMP-12 vaccine NSs that is able to inhibit the transcription activity of constitutive
promoters [61, 69]. Germline-encoded receptors (e.g. TLRs, RIG-I-like) recognize viral nucleic
acids of the vaccine. Complex networks of signal transduction converge on multiple transcrip-
tion factors that included AP-1, STAT1/3/6, and IRF9. The interplay of these transcription fac-
tors determines the transcriptional response profile of downstream genes and leads to a
dynamic expression of genes that produce a cascade of biological responses necessary to initiate
and achieve long-term immune protection to RVFV.
Immediately following vaccine inoculation, it appears that the vaccine viral components
have successfully invaded the host cells, triggering the induction of a family of pleiotropic cyto-
kines known as the IFNs (interferons) as evidenced by the activation of the type I interferon
signaling and the significant perturbation of the interferon stimulated genes (ISGs) IFI16,
MX1, IFIH1, IFI44, IFNAR2, IFITM1/2, IRF2BP2, IR12RB1, IRF1, IRF3 and IRF9 within the
first 5 days post immunization. IFN interactions with their receptors induce a set of IFN-stimu-
lated genes that inhibit viral replication and increase the lytic potential of natural killer (NK)
cells. It has been reported [70] that Type-I IFNs modulate the adaptive immune response by
increasing MHC-I or MHC-II (Major Histocompatibility Complex Class-I/II) expression to
promote antigen presentation, also promoting T-Cell survival and stimulating dendritic cell
maturation. However, in our study, the MHC-I genes were only minimally expressed and the
only significantly expressed MHC gene was HLA-DOA, (MHC class II) and the MHC-II trans-
activator gene, CIITA. The gene, CIITA, encodes a protein essential for transcriptional activity
of the HLA-II promoter. This protein is located in the nucleus and acts as a positive regulator
of MHC-II transcription. This gene has been functionally associated with cellular response to
exogenous dsRNA and interferon-gamma-mediated signaling pathway.
At later time points, we observed the triggering/activation of T cells and B cells, suggesting
that cell-mediated immunity was beginning as early as day 3 post vaccination. A number of
genes were expressed that are associated with T cell activation and signaling that included
PIK3R1, PIK3R3, CHUK, ICOS, NFkappaB2, RNUX2, AKT2, CCR2, CD48, RELA, STAT5A,
TNFSF14, TLR4, CD72, ITFG2, NR1D1, and PTPN6. Interestingly, the majority of these genes
was significantly modulated at days 5 and 6 and became less expressed at day 7 and beyond.
Complementary to our work, a recent study using a deletion mutant of arMP-12, arMP12-del-
taNSm21/384, showed rapid progression of protective antibodies after vaccination and after
challenge with the wild-type strain ZH501 [19]. This rapid antibody response to wild-type
challenge was concomitant with INF-γ expression, indicating a cell-mediated immune
response. Our data indicate that the parent arMP-12 strain is capable of inducing the adaptive
immune response machinery quickly after vaccination.
The primary objective of this retrospective study was to identify a set of genes for predicting
protective immunity. The selection of the genes was based on a systems biology top-down
approach in which we narrowed our focus on genes within pathways and GO terms that were
significantly perturbed and had SWC correlates to the PRNT80 onset of protective immunity.
Novel in this approach was the fact that we employed a sliding time window to find trajectory
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responses at earlier time points that have high positive or negative correlation to the PRNT80
response trajectory at time points just prior to and at the point of protective seroconversion.
An additional novel step was then employed to learn the gene regulatory network (GRN)
from the selected set of genes. This step allowed us to further identify genes that had strong reg-
ulatory relationships among other upstream and downstream genes. Finally, the combination
of SWC correlates to PRNT80 and the GRN relationships were used to select the genes used in
constructing and training the predictive DBN model. The model performance was quite good
when the model was tested with gene expression profiles from Time -5, -4, or -3 pSN and was
successful in predicting a future PRNT80 value at Time –1, –0, and 1 pSN. In summary, the
model had an overall sensitivity = 93% and specificity = 100%. While the limited number of
replicates restricts our ability to fully test the robustness of this model, it does allow us to access
our approach to developing models predicting protective immunity.
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